OBJECTIVE: To clarify the role and mechanism of CCL2 in regulating the biological functions of endometrial stromal cells (ESCs). DESIGN: The CCL2 effect on the viability, proliferation, and invasion in the eutopic ESCs from endometriosis. SETTING: Research laboratories. PATIENT(S): Patients with endometriosis aged 23-47 years. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Signal transduction and downstream molecules from CCR2. RESULT(S): We have found that the secretion of CCL2 by the eutopic ESCs from endometriosis is higher than that of healthy ESCs without endometriosis. The CCL2 can enhance the viability, proliferation, and invasion of ESCs in a dosage and time-dependent manner. Anti-CCL2 neutralizing antibody and CCR2 antagonist can completely abolish the increase in viability, proliferation, and invasiveness of ESCs induced by CCL2. The CCL2 can increase the expression of proliferating cell nuclear antigen, survivin, and matrix metalloproteinase 2, and decrease the expression of tissue inhibitor of metalloproteinase 1 and 2, and promote the viability, proliferation and invasiveness of ESCs by activating Akt and MAPK/Erk1/2 signal pathway, but not p38 and JNK signal pathway. CONCLUSION(S): CCL2 might play an important role in regulating the functions of ESCs through Akt and MAPK/Erk1/2 signal pathway, and overexpression of CCL2 in ESCs and peritoneal fluid (PF) would lead to onset and development of endometriosis.
OBJECTIVE: To clarify the role and mechanism of CCL2 in regulating the biological functions of endometrial stromal cells (ESCs). DESIGN: The CCL2 effect on the viability, proliferation, and invasion in the eutopic ESCs from endometriosis. SETTING: Research laboratories. PATIENT(S): Patients with endometriosis aged 23-47 years. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Signal transduction and downstream molecules from CCR2. RESULT(S): We have found that the secretion of CCL2 by the eutopic ESCs from endometriosis is higher than that of healthy ESCs without endometriosis. The CCL2 can enhance the viability, proliferation, and invasion of ESCs in a dosage and time-dependent manner. Anti-CCL2 neutralizing antibody and CCR2 antagonist can completely abolish the increase in viability, proliferation, and invasiveness of ESCs induced by CCL2. The CCL2 can increase the expression of proliferating cell nuclear antigen, survivin, and matrix metalloproteinase 2, and decrease the expression of tissue inhibitor of metalloproteinase 1 and 2, and promote the viability, proliferation and invasiveness of ESCs by activating Akt and MAPK/Erk1/2 signal pathway, but not p38 and JNK signal pathway. CONCLUSION(S): CCL2 might play an important role in regulating the functions of ESCs through Akt and MAPK/Erk1/2 signal pathway, and overexpression of CCL2 in ESCs and peritoneal fluid (PF) would lead to onset and development of endometriosis.
Authors: T T Piltonen; J Chen; D W Erikson; T L B Spitzer; F Barragan; J T Rabban; H Huddleston; J C Irwin; L C Giudice Journal: J Clin Endocrinol Metab Date: 2013-07-03 Impact factor: 5.958
Authors: Devashana Gupta; M Louise Hull; Ian Fraser; Laura Miller; Patrick M M Bossuyt; Neil Johnson; Vicki Nisenblat Journal: Cochrane Database Syst Rev Date: 2016-04-20